

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2018/027176 A1**

(43) International Publication Date  
08 February 2018 (08.02.2018)

(51) International Patent Classification:

C12Q 1/68 (2006.01) G06F 19/24 (2011.01)  
G06F 19/18 (2011.01)

(21) International Application Number:

PCT/US2017/045583

(22) International Filing Date:

04 August 2017 (04.08.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/371,660	05 August 2016 (05.08.2016)	US
62/372,616	09 August 2016 (09.08.2016)	US
62/481,561	04 April 2017 (04.04.2017)	US

(71) Applicants: **THE BROAD INSTITUTE, INC.** [US/US];  
415 Main Street, Cambridge, Massachusetts 02142 (US).  
**MASSACHUSETTS INSTITUTE OF TECHNOLOGY**  
[US/US]; 77 Massachusetts Avenue, Cambridge, Massa-  
chusetts 02139 (US).

(72) Inventors; and

(71) Applicants: **LIU, Yaping** [US/US]; c/o Massachusetts In-  
stitute of Technology, 77 Massachusetts Avenue, Cam-  
bridge, Massachusetts 02139 (US). **KELLIS, Manolis**  
[US/US]; c/o Massachusetts Institute of Technology, 77  
Massachusetts Avenue, Cambridge, Massachusetts 02139  
(US). **ADALSTEINSSON, Viktor** [US/US]; c/o The  
Broad Institute, Inc., 415 Main Street, Cambridge, Mass-  
achusetts 02142 (US). **ZHANG, Zhizhuo** [US/US]; c/o  
Massachusetts Institute of Technology, 77 Massachusetts  
Avenue, Cambridge, Massachusetts 02139 (US).

(74) Agent: **HUNTER-ENSOR, Melissa**; Greenberg Traurig,  
LLP, One International Place, Suite 2000, Boston, Massa-  
chusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: METHODS FOR GENOME CHARACTERIZATION

(57) Abstract: As described below, disclosed herein are methods of analyzing DNA methylation in cell-free DNA (cfDNA) and ge-  
nomic DNA (gDNA) from sequencing data.



WO 2018/027176 A1

## **METHODS FOR GENOME CHARACTERIZATION**

### **CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit of and priority to U.S. Provisional Patent  
5 Application serial number 62/371,660 filed August 5, 2016, U.S. Provisional Patent  
Application serial number 62/372,616 filed August 9, 2016, and U.S. Provisional Patent  
Application serial number 62/481,561 filed April 4, 2017, each of which is incorporated  
herein by reference in its entirety.

### **10 STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH**

This invention was made with government support under Grant No. HG007610  
awarded by the National Institutes of Health. The government has certain rights in the  
invention.

15

### **BACKGROUND**

Cells release cell-free DNA (cfDNA) when they die. The detection of which cells are  
releasing cfDNA (or which cells are dying) may have significant potential as a clinical  
diagnostic in multiple disease states including, but not restricted to, cancer.

20 Using cancer as a non-limiting example, cell free circulating tumor DNA (ctDNA)  
has been shown to be an emerging non-invasive biomarker to monitor tumor progression in  
cancer patients. In late stage cancer patients, elevated ctDNA has been found not only from  
tumors, but also from normal tissues. Thus, the identification of ctDNA's tissue-of-origin is  
critical to understand the mechanism of tumor progression, and provide an accurate clinical  
25 prognosis and/or diagnosis.

Recent efforts to identify ctDNA's tissue-of-origin utilize ctDNA's epigenomic status,  
such as DNA methylation and nucleosome spacing.

Proof-of-concept for using methylation to deconvolve tissue-of-origin largely relies  
upon methylation levels ascertained from deep coverage (e.g., 30x) bisulfite sequencing. It  
30 also requires selection of different markers for different specific diseases. Limitations of  
existing technologies include, for example: (1) For nucleosome positioning, lack of reference  
nucleosome maps in different tumor and normal tissues has limited its application to tissue-  
of-origin deconvolution; and (2) For DNA methylation, large DNA degradation during whole

genome bisulfite sequencing (WGBS) library preparation, even with current low-input DNA technology, remains a major hurdle for its clinical application. Therefore, there is a significant need for improved methods related to the analysis of DNA methylation in cfDNA or ctDNA samples in order to reveal clinically relevant biomarkers and to identify tissue of origin.

### SUMMARY

As described below, disclosed herein are methods of analyzing DNA methylation in cell-free DNA (cfDNA) and genomic DNA (gDNA) from sequencing data.

10 In one aspect, the invention generally features methods of characterizing DNA in a biological sample, the method involving isolating fragments of DNA from a biological sample, constructing a library comprising the fragments, sequencing the library, and detecting alterations in the fragmentation pattern in methylated and unmethylated DNA of cell free DNA (cfDNA) and genomic DNA (gDNA), where the fragmentation pattern in each DNA  
15 fragment identifies the DNA methylation pattern.

In another aspect, the invention provides a method of characterizing DNA in a biological sample, the method involving isolating fragments of DNA from a biological sample, constructing a library comprising the fragments, sequencing the library, and detecting alterations in the fragment length, fragment coverage, and distance to fragment end in  
20 methylated and unmethylated DNA of cell free DNA and genomic DNA, where the fragmentation pattern in each DNA fragment identifies the DNA methylation pattern, thereby indicating that at least a fragment of the DNA in the sample was derived from a diseased cell or was derived from a healthy cell. In some embodiments, the diseased cell is derived from a patient having cancer, diabetes, kidney disease, Alzheimer's disease, myocardial infarction, stroke, autoimmune disorders, transplant rejection, Multiple sclerosis, type I diabetes, a  
25 cancer or disease having a pre-determined tissue of origin, and a disease that results in increased cell death.

In another aspect, the invention provides a method of identifying a subject as having a disease or cancer, the method involving isolating fragments of DNA from a biological  
30 sample, constructing a library comprising the fragments, sequencing the library, and detecting alterations in the fragmentation pattern in methylated and unmethylated DNA of cell free DNA and genomic DNA, where the detection of differences in the fragmentation pattern indicates that the subject has a disease or cancer, and failure to detect such alterations

indicates that the subject does not have a disease or cancer; thereby identifying the subject as having or not having a disease or cancer.

In another aspect, the invention provides a method of monitoring a subject's response to a disease or cancer treatment, the method involving (a) isolating fragments of DNA from a biological sample obtained from the subject prior to disease or cancer treatment, constructing  
5 a library comprising the fragments, sequencing the library, detecting alterations in the fragmentation pattern in methylated and unmethylated DNA of cell free DNA and genomic DNA; (b) isolating fragments of DNA from a biological sample obtained from the subject after commencing disease or cancer treatment, constructing a library comprising the  
10 fragments, sequencing the library, detecting alterations in the fragmentation pattern in methylated and unmethylated DNA of cell free DNA and genomic DNA, and (c) comparing the prior and after treatment alterations in the fragmentation pattern in methylated and unmethylated DNA of cell free DNA and genomic DNA, thereby monitoring the subject's response to a disease or cancer treatment.

In another aspect, the invention provides a method of diagnosing the presence or  
15 absence of a disease or cancer in a subject, the method involving isolating fragments of DNA from a biological sample, constructing a library comprising the fragments, sequencing the library; and comparing the subject's alterations in the fragmentation pattern in methylated and unmethylated DNA of cell free DNA and genomic DNA to a healthy reference sample;  
20 where the detection of differences in the fragmentation pattern between the subject and the reference sample indicates that the subject does have a disease or cancer, and failure to detect such alterations indicates that the subject does not have a disease or cancer.

In various embodiments of any aspect delineated herein, prior to isolating fragments of DNA from a biological sample, the methods involve contacting the gDNA with an enzyme  
25 that is capable of cutting the DNA at hypersensitive sites. In various embodiments of any aspect delineated herein, the enzyme is Deoxyribonuclease I (DNase I) or Transposase (*e.g.*, TN5). In various embodiments of any aspect delineated herein, the sample comprises a limited amount of DNA (*e.g.*, at least 1, 2, 4, 5, 10, 15, 20 ng of DNA).

In various embodiments of any aspect delineated herein, the method identifies the  
30 binary methylation status at each CpG in each DNA fragment.

In various embodiments of any aspect delineated herein, the sequencing is ultra-low pass, exome sequencing, whole genome sequencing, or deep sequencing. In various embodiments of any aspect delineated herein, the sequencing is at about 0.01-30X genome

sequencing coverage. In various embodiments of any aspect delineated herein, the sequencing is capture based sequencing. In some embodiments, the capture based sequencing has off-target reads that span the genome.

In various embodiments of any aspect delineated herein, the biological sample is a  
5 tissue sample or a liquid biological sample selected from the group consisting of blood, plasma, serum, cerebrospinal fluid, phlegm, saliva, urine, semen, prostate fluid, breast milk, and tears. In various embodiments of any aspect delineated herein, the biological sample is a fresh or archival sample derived from a subject having a cancer selected from the group consisting of prostate cancer, metastatic prostate cancer, breast cancer, triple negative breast  
10 cancer, lung cancer, multiple myeloma, pancreatic cancer, and colon cancer. In various embodiments of any aspect delineated herein, the tissue of origin of the biological sample is selected from the group consisting of an esophageal cell, B-Cell, breast, brain cortex, prostate cancer, small intestine, heart, large intestine, liver, lung, neutrophil, pancreas, or T-Cell.

In another aspect, the invention provides a computer-implemented method, involving  
15 receiving, by at least one computer processor executing specific programmable instructions configured for the method, sequence data; filtering, by the at least one computer processor, the sequence data from the training set, based on the following parameters: (i) the fragment length of each individual DNA fragment within the plurality; (ii) the fragment coverage; (iii) the distance to fragment end; and (iv) a reference methylation pattern; generating, by the at  
20 least one computer processor, a Bayesian non-homogenous Hidden Markov Model, using the parameters (i) to (iv) in the steps above, to predict DNA methylation patterns from DNA sequence reads; receiving, by at least one computer processor executing specific programmable instructions configured for the method, sequence data, where the sequence data is obtained from cell free DNA or genomic DNA isolated from a biological sample  
25 obtained from a subject, where the gDNA has been contacted with an enzyme; generating, by the at least one computer processor, from the sample sequence data, data corresponding to (i) the fragment length of each individual DNA fragment within the plurality; (ii) the fragment coverage; and (iii) the distance to fragment end; and determining, by the at least one computer processor, using the Bayesian non-homogenous Hidden Markov Model, using the  
30 parameters (i) to (iii) ((i) the fragment length of each individual DNA fragment within the plurality; (ii) the fragment coverage; and (iii) the distance to fragment end), the predicted DNA methylation pattern of the ctDNA or gDNA in the biological sample.

In various embodiments of the computer-implemented method aspect delineated herein, the predicted DNA methylation pattern of the ctDNA is deconvoluted, by the at least one computer processor, using a non-overlapping window analysis and quadratic programming, to obtain the tissue of origin of the biological sample.

5 In various embodiments of the computer-implemented method aspect delineated herein, the enzyme is capable of cutting the DNA at hypersensitive sites. In some embodiments, the enzyme is Deoxyribonuclease I (DNase I) or Transposase (*e.g.*, TN5). In various embodiments of the computer-implemented method aspect delineated herein, the sample comprises a limited amount of DNA (*e.g.*, at least 1-20 ng of DNA).

10 In various embodiments of the computer-implemented method aspect delineated herein, the method identifies the binary methylation status at each CpG in each DNA fragment.

In various embodiments of the computer-implemented method aspect delineated herein, the sequencing is ultra-low pass, exome sequencing, whole genome sequencing, or  
15 deep sequencing. In various embodiments of any aspect delineated herein, the sequencing is at about 0.01-30X genome sequencing coverage. In various embodiments of the computer-implemented method aspect delineated herein, the sequencing is capture based sequencing. In some embodiments, the capture based sequencing has off-target reads that span the genome.

In various embodiments of the computer-implemented method aspect delineated  
20 herein, the biological sample is a tissue sample or a liquid biological sample selected from the group consisting of blood, plasma, serum, cerebrospinal fluid, phlegm, saliva, urine, semen, prostate fluid, breast milk, and tears. In various embodiments of the computer-implemented method aspect delineated herein, the biological sample is a fresh or archival sample derived from a subject having a cancer selected from the group consisting of prostate cancer,  
25 metastatic prostate cancer, breast cancer, triple negative breast cancer, lung cancer, multiple myeloma, pancreatic cancer, and colon cancer. In various embodiments of the computer-implemented method aspect delineated herein, the reference methylation pattern is derived from a patient having cancer, diabetes, kidney disease, Alzheimer's disease, myocardial infarction, stroke, autoimmune disorders, transplant rejection, Multiple sclerosis, type I  
30 diabetes, a cancer or disease having a pre-determined tissue of origin, and a disease that results in increased cell death. In various embodiments of the computer-implemented method aspect delineated herein, the tissue of origin of the biological sample is selected from the

group consisting of an esophageal cell, B-Cell, breast, brain cortex, prostate cancer, small intestine, heart, large intestine, liver, lung, neutrophil, pancreas, or T-Cell.

### Definitions

5 Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person of ordinary skill in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed.,  
10 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.

"Tumor derived DNA" means DNA that is derived from a cancer cell rather than a healthy control cell. Tumor derived DNA often includes structural changes that are  
15 indicative of cancer. Such structural changes may be at the level of the chromosome, which includes aneuploidy (abnormal number of chromosomes), duplications, deletions, or inversions, or alterations in sequence. In particular embodiments, tumor derived DNA has changes in fragment length or methylation.

By "alteration" is meant a change relative to a reference.

20 "Biological sample" as used herein refers to a sample obtained from a biological subject, including sample of biological tissue or fluid origin, obtained, reached, or collected in vivo or in situ, that contains or is suspected of containing polynucleotides. A biological sample also includes samples from a region of a biological subject containing precancerous or cancer cells or tissues. Such samples can be, but are not limited to, organs, tissues,  
25 fractions and cells isolated from mammals including, humans such as a patient, mice, and rats. Biological samples also may include sections of the biological sample including tissues, for example, frozen sections taken for histologic purposes.

In this disclosure, "comprises," "comprising," "containing" and "having" and the like can have the meaning ascribed to them in U.S. Patent law and can mean "includes,"  
30 "including," and the like; "consisting essentially of" or "consists essentially" likewise has the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is

recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.

By “disease” is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include cancer, diabetes, kidney disease, Alzheimer’s disease, myocardial infarction, stroke, autoimmune disorders, transplant rejection, multiple sclerosis, type I diabetes, a cancer, or any disease that results in an increase in cell death. For example, an increase in apoptotic or necrotic cell death.

By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.

The terms “isolated,” “purified,” or “biologically pure” refer to material that is free to varying degrees from components which normally accompany it as found in its native state. “Isolate” denotes a degree of separation from original source or surroundings. “Purify” denotes a degree of separation that is higher than isolation. A “purified” or “biologically pure” protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this disclosure is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high performance liquid chromatography. The term “purified” can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.

By “isolated polynucleotide” is meant a nucleic acid (e.g., a DNA) that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of this disclosure is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment



produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence.

5 By “marker” is meant any protein or polynucleotide having an alteration in methylation, sequence, copy number, expression level or activity that is associated with a disease or disorder.

By “neoplasia” is meant a disease that is associated with inappropriately high levels of cell division, inappropriately low levels of apoptosis, or both. For example, cancer is an  
10 example of a neoplastic disease. Examples of cancers include, without limitation, leukemias (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (Hodgkin’s disease,  
15 non-Hodgkin’s disease), Waldenstrom’s macroglobulinemia, heavy chain disease, and solid tumors such as sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast  
20 cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm’s tumor, cervical cancer, uterine cancer, testicular  
25 cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma).

A “reference genome” is a defined genome used as a basis for genome comparison or  
30 for alignment of sequencing reads thereto. A reference genome may be a subset of or the entirety of a specified genome; for example, a subset of a genome sequence, such as exome sequence, or the complete genome sequence.

By “subject” is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, rodent, or feline.

Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of  
5 numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

As used herein, the terms “treat,” “treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that,  
10 although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.

Unless specifically stated or obvious from context, as used herein, the term “or” is understood to be inclusive. Unless specifically stated or obvious from context, as used herein, the terms “a”, “an”, and “the” are understood to be singular or plural.

Unless specifically stated or obvious from context, as used herein, the term “about” is  
15 understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.

The recitation of a listing of chemical groups in any definition of a variable herein  
20 includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

Any compositions or methods provided herein can be combined with one or more of  
25 any of the other compositions and methods provided herein.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

FIG. 1A, FIG. 1B, FIG. 2, FIG. 3, FIG. 4, FIG. 5, FIG. 6, and FIG. 7 show that DNA methylation can be inferred from high coverage whole genome sequencing.

FIG. 1A provides a depiction of a method of determining the tissue-of-origin of  
30 ctDNA according to some embodiments of the present disclosure.

FIG. 1B provides a schematic illustrating a rationale for the use of DNA methylation in determining the tissue-of-origin of ctDNA. Part 4 (bottom-right) shows a diagram about

why DNA methylation could be inferred from whole genome sequencing in cell-free DNA (cfDNA).

FIG. 2 includes two graphs showing the differences of distance to the fragment end in methylated and unmethylated CpGs of cfDNA and genomic DNA (gDNA)

5 FIG. 3 provides an ROC curve for the performance of ccInference in fragments with different numbers of CpGs.

FIG. 4 is a graph that provides an average ground truth (WGBS) and predicted (WGS) DNA methylation level at CpG island promoter regions from individuals with cancer and healthy individuals.

10 FIG. 5 is a Ven diagram that provides the overlap of differentially methylated regions (DMRs) called at ground truth and predicted DNA methylation.

FIG. 6 provides a heatmap of ground truth (WGBS) and predicted (WGS) DNA methylation level around the center of DMRs called in WGBS (-300bp to 300bp).

15 FIG. 7 provides an example intergenic region to show ground truth (WGBS) and predicted (WGS) DNA methylation level.

FIG. 8 includes a graph and a heat map that shows that DNA methylation and tissue-of-origin can be inferred from ultra-low-pass whole genome sequencing. FIG. 8 provides Pearson correlation of the methylation level within 1kb non-overlapped bins at 104 paired Ultra Low Pass (ULP)-WGS and ULP-WGBS.

20 FIG. 9, FIG. 10A, FIG. 10B, and FIG. 10C show fragmentation differences in methylated and unmethylated DNA at cfDNA and gDNA.

FIG. 9 includes four scatter plots that provide a correlation between mean DNA methylation and fragment length in cfDNA and gDNA.

25 FIG. 10A includes two graphs that provide a correlation between DNA methylation level at CpGs within and across fragment at cfDNA and gDNA.

FIG. 10B includes two graphs that quantitate differences of normalized coverage in methylated and unmethylated CpGs at cfDNA and gDNA.

FIG. 10C includes two graphs that show differences of fragment length in methylated and unmethylated CpGs at cfDNA and gDNA.

30 FIG. 11 provides a scheme showing the ccInference pipeline.

FIG. 12 provides a Precision-Recall curve showing the performance of ccInference in fragments with different number of CpGs.

FIG. 13 includes two panels that provide a correlation at ground truth (WGBS) and predicted (WGS) DNA methylation level. Smoothed scatterplot of methylation level at (FIG. 13A) single CpG and (FIG. 13B) within 1kb non-overlapped bins at one paired high coverage WGS and WGBS in healthy individual.

5 FIG. 14 includes two graphs that provide average ground truth (WGBS) and predicted (WGS) DNA methylation level at (FIG. 14A) intergenic CTCF motif regions and (FIG. 14B) exons from cancer and healthy individuals.

FIG. 15A, FIG. 15B, FIG. 15C, FIG. 15D, and FIG. 15E provide example regions that are often hypermethylated in prostate cancer patients. (FIG. 15A) APC, (FIG. 15B) CDKN2A, (FIG. 15C) CAV1, (FIG. 15D) ESR1, (FIG. 15E) TNFRSF10C.

FIG. 16A, FIG. 16B, FIG. 16C, and FIG. 16D are pie charts that provide tissue-of-origin prediction based on ground truth (WGBS) and predicted (WGS) DNA methylation level in cancer and healthy individuals.

FIG. 17 includes two graphs that provide average ground truth (ULP-WGBS) (FIG. 17A) and predicted (ULP-WGS) (FIG. 17B) DNA methylation level at CpG island promoter region by from cancer and healthy individuals.

FIG. 18 shows a depiction of the inference of tissue-of-origin of cfDNA from ULP-WGBS according to some embodiments of the present disclosure. ER+: denotes Estrogen Receptor positive.

20 FIG. 19A shows results obtained using the methods of this disclosure to determine cfDNA's tissue-of-origin status by inferred DNA methylation level at ULP-WGS from ENCODE cell line samples H1, HepG2, K562, and GM12878.

FIG. 19B shows an analysis of cfDNA tissue of origin status.

FIG. 19C includes a box plot and a scatter plot that show Prostate Specific Antigen (PSA) levels characterized in patient samples (top panel) and the cfDNA yield as a function of fraction of cfDNA from liver (bottom panel).

### DETAILED DESCRIPTION

As described below, disclosed herein are methods of using ultra low pass-whole genome bisulfite sequencing (ULP-WGBS) to determine the tissue of origin in cfDNA isolated from a biological sample.

Analysis of DNA methylation in cell-free DNA (cfDNA) may reveal clinically relevant biomarkers, but requires specialized protocols and sufficient input material that

limits its applicability. Millions of cfDNA samples have been profiled by genomic sequencing. Disclosed herein are methods that establish a Bayesian non-homogeneous Hidden Markov Model to identify single base-pair resolution DNA methylation of cfDNA directly from whole-genome sequencing data, and validated in 107 pairs of whole-genome  
5 and whole-genome bisulfite sequencing data.

A machine learning approach was developed to infer the base pair resolution DNA methylation level from fragment size information in whole genome sequencing (WGS). The predicted DNA methylation, from not only high coverage but also dozens of ultra-low-pass WGS (ULP-WGS), showed high concordance with the ground truth DNA methylation level  
10 from whole genome bisulfite sequencing (WGBS) in the same cancer patients. Furthermore, by using hundreds of whole genome bisulfite sequencing datasets from different tumor and normal tissues/cells as the reference map, cfDNA's tissue-of-origin status was deconvoluted by inferred DNA methylation level at ULP-WGS from hundreds of prostate cancer samples and healthy individuals. The cfDNA's tissue-of-origin status in cancer patients showed high  
15 concordance with confirmed metastasis tissues from physicians. Interestingly, some clinical information, such as cancer grades/stages, seemed to be correlated with cfDNA's tissue-of-origin status. Overall, the methods here provide for cfDNA's application in clinical diagnosis and monitoring.

Referring to FIG. 1A and FIG. 1B, in some aspects, the methods disclosed herein  
20 generally provide computational methods to identify ctDNA's tissue-of-origin by inferring its DNA methylation pattern from DNA fragment information obtained from ULP-WGBS.

As used herein, the term "bisulfite sequencing" refers to the use of bisulfite treatment of DNA to determine its pattern of methylation. Without intending to be limited to any particular theory, the treatment of DNA with bisulfite converts cytosine residues to uracil, but  
25 leaves 5-methylcytosine residues unaffected. Therefore, DNA that has been treated with bisulfite retains only methylated cytosines. Thus, bisulfite treatment introduces specific changes in the DNA sequence that depend on the methylation status of individual cytosine residues, yielding single-nucleotide resolution information about the methylation status of a segment of DNA.

The methods disclosed herein overcome the challenge of screening large numbers of  
30 blood samples to identify ctDNA's tissue-of-origin. This allows identification of ctDNA's tissue-of-origin in a sample from a trivial amount of sequencing (~0.1x coverage or \$20).

In one aspect, the methods disclosed herein feature a computational approach to identify the ctDNA's tissue-of-origin by inferring its DNA methylation pattern from DNA fragment information obtained from ULP-WGBS.

Referring to FIG. 1, FIG. 9, FIG. 10, in some aspects, the identification of the  
5 ctDNA's tissue-of-origin is inferred by the correlation between DNA methylation and DNA fragment length. Without intending to be limited to any particular theory, the lengths of methylated DNA fragments are different to the lengths of unmethylated DNA fragments.

In some embodiments, a Hidden Markov Model framework is used to predict DNA methylation at each CpG site within a genome.

10 Referring to FIG. 11, FIG. 13, FIG. 14, in some embodiments, the methods disclosed herein provide a computer implemented method, comprising:

- (a) receiving, by at least one computer processor executing specific programmable instructions configured for the method, sequence data;
- (b) filtering, by the at least one computer processor, the sequence data from the  
15 training set, based on the following parameters: (i) the fragment length of each individual DNA fragment within the plurality; (ii) the fragment coverage; (iii) the distance to fragment end; and (iv) a reference methylation pattern;
- (c) generating, by the at least one computer processor, a Bayesian non-homogenous Hidden Markov Model, using the parameters (i) to (iv) in step (b) above, to  
20 predict DNA methylation patterns from DNA sequence reads;
- (d) receiving, by at least one computer processor executing specific programmable instructions configured for the method, sequence data,

wherein the sequence data is obtained from cell free DNA or genomic  
DNA isolated from a biological sample obtained from a  
25 subject, wherein the gDNA has been contacted with an enzyme;

- (e) generating, by the at least one computer processor, from the sample sequence data, data corresponding to (i) the fragment length of each individual DNA fragment within the plurality; (ii) the fragment coverage; and (iii) the distance to fragment end; and  
30
- (f) determining, by the at least one computer processor, using the Bayesian non-homogenous Hidden Markov Model, using the parameters (i) to (iii) in step (e) above, the predicted DNA methylation pattern of the ctDNA or gDNA in the biological sample.

In another aspect, the methods disclosed herein feature a computational approach to deconvolute ctDNA's tissue-of-origin status by using only fragment information from ULP-WGBS in ctDNA and DNA methylation levels from publically available disease and normal ULP-WGBS datasets.

5 Referring to FIG. 18, in some embodiments, the predicted DNA methylation pattern of the ctDNA is deconvoluted, by the at least one computer processor, using a non-overlapping window analysis and quadratic programming, to obtain the tissue of origin of the biological sample.

10 In another aspect, the methods disclosed herein feature a method of monitoring the disease state of a subject, the method involving isolating fragments of ctDNA from two or more biological samples, where the first biological sample is obtained at a first time point and a second or subsequent biological sample is obtained at a later time point; constructing two or more libraries each containing fragments from the samples; sequencing the libraries to at least about 0.01-5X exome or genome-wide sequencing coverage using ULP-WGBS; and  
15 comparing the methylation patterns in the sequence over time, thereby monitoring the disease state of the subject. In another embodiment, the first time point is prior to treatment.

In another aspect, the methods disclosed herein provide a method of characterizing the efficacy of treatment of a subject having a disease characterized by an alteration in methylation, the method involving isolating fragments of ctDNA from two or more biological  
20 samples derived from a subject undergoing cancer therapy, where the first biological sample is obtained at a first time point and a second or subsequent biological sample is obtained at a later time point; constructing two or more libraries each containing fragments from the samples; sequencing the libraries to at least about 0.01-30X (e.g., 0.01, 0.05, 0.1, 1, 2, 5, 10, 15, 20, 25, 30X) genome or exome -wide sequencing coverage; and comparing the  
25 methylation patterns in the sequence over time, thereby characterizing the efficacy of treatment. In another embodiment, samples are collected at 5, 15, or 30 minute intervals while a cancer therapy is administered. In another embodiment, samples are collected at 3, 6, 9, 12, 24, 36, or 72 hour intervals. In another embodiment, samples are collected at 1, 2, 3, 4, 5, or 6 week intervals.

30 In various embodiments of any of the above aspects or any other aspect of the methods delineated herein, the DNA is ctDNA. In other embodiments, the exome wide or genome wide sequencing coverage using ULP-WGBS is any one or more of 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, and 5X.

In still other embodiments, the biological sample is a tissue sample or a liquid biological sample that is blood, plasma, serum, cerebrospinal fluid, phlegm, saliva, urine, semen, prostate fluid, breast milk, and/or tears. In still other embodiments, the sample is derived from a subject having or suspected of having a neoplasia. In still other embodiments, the sample is a fresh or archival sample derived from a subject having a cancer that is prostate cancer, metastatic prostate cancer, breast cancer, triple negative breast cancer, lung cancer, colon cancer, or any other cancer containing aneuploid cells. In still other embodiments, the cancer is metastatic castration resistant prostate cancer or metastatic breast cancer. In still other embodiments, the patient is being treated for a neoplasia.

In some aspects, the method can diagnose at least one disease, selected from the group consisting of cancer, diabetes, kidney disease, Alzheimer's disease, myocardial infarction, stroke, autoimmune disorders, transplant rejection, multiple sclerosis, type I diabetes, a cancer, and a disease that results in increased cell death.

In another embodiment, the second or subsequent time point is during the course of treatment. In another embodiment, the disease state is a cancer that is any one of prostate cancer, metastatic prostate cancer, breast cancer, triple negative breast cancer, lung cancer, and colon cancer.

In some aspects, the method is utilized as a non-invasive pre-natal diagnosis.

In some aspects, the methods disclosed herein feature a computational approach to identify the ctDNA's tissue-of-origin by inferring its DNA methylation pattern from DNA fragment information obtained from either ULP-WGBS, or ultra-low pass-whole genome sequencing (ULP-WGS).

### **Whole Genome Sequencing**

The methods disclosed herein feature a method of characterizing DNA in a biological sample, the method involving isolating fragments of ctDNA from a biological sample; constructing a library containing the fragments; sequencing the library to about 0.1X genome or exome -wide sequencing coverage using ULP-WGBS; and detecting methylation patterns in the sequence.

Whole genome sequencing (also known as "WGS", full genome sequencing, complete genome sequencing, or entire genome sequencing) is a process that determines the complete DNA sequence of an organism's genome. A common strategy used for WGS is shotgun sequencing, in which DNA is broken up randomly into numerous small segments,



which are sequenced. Sequence data obtained from one sequencing reaction is termed a “read.” The reads can be assembled together based on sequence overlap. The genome sequence is obtained by assembling the reads into a reconstructed sequence.

Whole Genome Bisulfite Sequencing interrogates DNA methylation patterns at single  
5 base pair resolution. The epigenetic marker 5-methylcytosine (5mC) is a stable covalent modification that can be measured from DNA isolated of any tissue type, including easily obtainable peripheral blood. There are a variety of different methods to assess genome-wide DNA methylation, including array-based, antibody-based, and sequencing-based approaches. In general, the method involves the use of bisulfite treatment that converts cytosines into  
10 uracils, but leaves methylated cytosines unchanged.

As described herein, and in PCT/US17/22792, which is incorporated herein in its entirety, ultra-low pass sequencing advantageously provides for the accurate characterization of genomic DNA at a significant savings of cost and time, thereby obviating the need for complete integrative clinical sequencing of the whole genome.

As used herein, the term “coverage” refers to the percentage of the genome covered  
15 by reads. In one embodiment, low coverage or ultra-low pass coverage is less than about 1X. Coverage also refers to, in shotgun sequencing, the average number of reads representing a given nucleotide in the reconstructed sequence. It can be calculated from the length of the original genome (G), the number of reads(N), and the average read length(L) as  $N \times L/G$ .  
20 Biases in sample preparation, sequencing, and genomic alignment and assembly can result in regions of the genome that lack coverage (that is, gaps) and in regions with much higher coverage than theoretically expected. It is important to assess the uniformity of coverage, and thus data quality, by calculating the variance in sequencing depth across the genome. The term depth may also be used to describe how much of the complexity in a sequencing  
25 library has been sampled. All sequencing libraries contain finite pools of distinct DNA fragments. In a sequencing experiment only some of these fragments are sampled.

### **Types of Samples**

This invention provides methods to extract and sequence a polynucleotide present in a  
30 sample. In one embodiment, the samples are biological samples generally derived from a human subject, preferably as a bodily fluid (such as blood, plasma, serum, cerebrospinal fluid, phlegm, saliva, urine, semen, prostate fluid, breast milk, or tears, or tissue sample (e.g. a tissue sample obtained by biopsy). In a further embodiment, the samples are biological

samples derived from an animal, preferably as a bodily fluid (such as blood, cerebrospinal fluid, phlegm, saliva, or urine) or tissue sample (e.g. a tissue sample obtained by biopsy). In still another embodiment, the samples are biological samples from *in vitro* sources (such as cell culture medium). cfDNA attached to a substrate may be first suspended in a liquid  
5 medium, such as a buffer or a water, and then subject to sequencing and/or analysis.

### **Diagnostics**

The methods disclosed herein feature a method of identifying a subject as having a neoplasia, the method involving isolating fragments of ctDNA from a biological sample;  
10 constructing a library containing the fragments; sequencing the library to about 0.1X genome or exome -wide sequencing coverage using ULP-WGBS; and detecting methylation patterns in the sequence.

Neoplastic tissues display alterations in their genome compared to corresponding normal reference tissues. Accordingly, this invention provides methods for detecting,  
15 diagnosing, or characterizing a neoplasia in a subject. The present invention provides a number of diagnostic assays that are useful for the identification or characterization of a neoplasia.

In one approach, diagnostic methods of the invention are used to detect changes in copy number and/or methylation in a biological sample relative to a reference (e.g., a  
20 reference determined by an algorithm, determined based on known values, determined using a standard curve, determined using statistical modeling, or level present in a control polynucleotide, genome or exome).

Methods of the invention are useful as clinical or companion diagnostics for therapies or can be used to guide treatment decisions based on clinical response/resistance. In other  
25 embodiments, methods of the invention can be used to qualify a sample for whole-exome sequencing.

A physician may diagnose a subject and the physician thus has the option to recommend and/or refer the subject to seek the confirmation/treatment of the disease. The availability of high throughput sequencing technology allows the diagnosis of large number  
30 of subjects.

### **Patient Monitoring**

The disease state or treatment of a patient having a cancer or other disease characterized alterations in methylation can be monitored using the methods and compositions of this invention. In one embodiment, the response of a patient to a treatment can be monitored using the methods and compositions of this invention. Such monitoring  
5 may be useful, for example, in assessing the efficacy of a particular treatment in a patient. Treatments amenable to monitoring using the methods of the invention include, but are not limited to, chemotherapy, radiotherapy, immunotherapy, and surgery. Therapeutics that alter the methylation of cfDNA are taken as particularly useful in this invention. In some  
10 In some embodiments, the therapeutic is azathioprine, 5-Azacytidine (AZA), 5-aza-2'-deoxycytidine. In some embodiments, the therapeutic is an HDAC inhibitor, such as Vorinostat, Entinostat, Trichostatin A, Mocetinostat, TMP195 or Romidepsin. In other embodiments, the therapeutic is a chemotherapy agent (*e.g.*, Avastin, Cytosan, Cytarabine, Decarbazine).

The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques),  
15 microbiology, cell biology, biochemistry and immunology, which are well within the purview of the person of ordinary skill. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook, 1989); "Oligonucleotide Synthesis" (Gait, 1984); "Animal Cell Culture" (Freshney, 1987); "Methods in Enzymology" "Handbook of Experimental Immunology" (Weir, 1996); "Gene  
20 Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Current Protocols in Molecular Biology" (Ausubel, 1987); "PCR: The Polymerase Chain Reaction", (Mullis, 1994); "Current Protocols in Immunology" (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of this invention, and, as such, may be considered in making and practicing this invention. Particularly useful techniques for  
25 particular embodiments will be discussed in the sections that follow.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of this invention, and are not intended to limit the scope of what the inventors regard as their invention.

30

#### **Analysis of DNA methylation in cell-free DNA**

Analysis of DNA methylation in cell-free DNA (cfDNA) has uncovered biomarkers of human diseases and conditions such as cancer, diabetes, and multiple sclerosis. Bisulfite

sequencing is the gold standard to study the single base pair resolution DNA methylation. However, extensive degradation during bisulfite treatment poses a major hurdle for low-input samples such as cfDNA—patients often harbor insufficient cfDNA for both genomic and epigenomic profiling. Millions of cfDNA samples are profiled by genomic sequencing in the context of non-invasive prenatal testing (NIPT) and tens of thousands from cancer patients. As disclosed herein, it was reasoned that if it were possible to estimate single base pair resolution DNA methylation from genomic sequencing of cfDNA, epigenomic analyses from cfDNA could become routinely feasible. Recent studies have shown a close correlation between DNA methylation and nucleosome positioning, and the size of cfDNA fragments is known to be closely related to nucleosomes and chromatosomes. Moreover, DNA fragment lengths in methylated and unmethylated cfDNA is found to be significantly different by MeDIP-seq (methylated DNA immunoprecipitation sequencing). It was hypothesized that if the boundaries of cfDNA fragments were biased by their association with nucleosomes, then the fragmentation patterns observed in each cfDNA molecule might reveal associated DNA methylation patterns (See FIG. 1B).

### EXAMPLES

#### *Example 1: Fragmentation differences in methylated and unmethylated DNA at cfDNA and gDNA*

To evaluate this hypothesis, the correlation between the length and mean methylation level of DNA fragments from publicly available WGBS of cfDNA and gDNA of buffy coat from several healthy individuals were first studied. (FIG. 9) Replicate samples of cfDNA showed wavy methylation shapes at nucleosomal length (166 bp) that were not present in the gDNA samples. It was then explored whether this fluctuation of DNA methylation level happens independently within each DNA fragment or across fragments. The Pearson correlation between DNA methylation at adjacent CpG's only showed a wavy like pattern from the CpGs within the same DNA fragment in cfDNA, but not in any other condition (FIG. 10A). This supports the hypothesis that the fragmentation pattern in each DNA fragment will provide the DNA methylation pattern by itself.

To identify the fragmentation features that are associated with the methylation status of each CpG, 1 million methylated and unmethylated CpGs from the cfDNA and gDNA of healthy individuals were randomly sampled and assessed the associated fragment length, normalized coverage, and the distance of each CpG to the end of each DNA fragment. All three of these features showed clearly separation between methylated and unmethylated

CpGs in the cfDNA but not the gDNA, which suggested the possibility to utilize these features to predict the binary methylation status at each CpG in each DNA fragment (FIG. 2, FIG. 10B, FIG. 10C).

5 *Example 2: The scheme of ccInference pipeline and performance using a Precision-Recall curve*

Based on these findings, a Bayesian based non-homogeneous Hidden Markov Model was built, named ccInference, to predict the methylation status of each CpG in each fragment of cfDNA (FIG. 11). The model was trained using high coverage WGBS of cfDNA, ignoring  
10 the methylation status at each CpG from WGBS, and then benchmarked the model performance by using the ground truth DNA methylation states from WGBS. After sampling the even number of the methylated and unmethylated CpGs, high performance based on the area under the receiver operating characteristic curve (auROC=0.73) was observed and even higher performance within fragments harboring greater numbers of CpG's (auROC=0.92, for  
15  $\geq 10$  CpG's per fragment), which may be due to utilization of states information from adjacent sites (FIG. 3). The performance using a Precision-Recall curve was also benchmarked and likewise observed higher accuracy for CpG's within CpG-rich regions. (FIG. 12) Considering these observations and the known tissue specificity of DNA methylation within CpG islands and shores (Irrizary 2009 Nature Genetics), all of the  
20 following model training and data analysis only in CpG island and shore regions ( $\pm 2$ kb of CpG islands) was performed.

*Example 3: Correlation at ground truth (WGBS) and predicted (WGS) DNA methylation level*

To explore whether bisulfite treatment could be avoided, independent WGS and  
25 WGBS libraries were generated from the same cfDNA sample from a healthy individual. The model was trained based on high coverage WGS, predicted the methylation status at each CpG in each fragment, and then aggregated the methylation status across the DNA fragments overlapping the same CpG sites to calculate the continuous methylation percentage level. By comparing estimated methylation level from WGS to the ground truth methylation level from  
30 WGBS, even with different coverage at each CpG sites, high Pearson correlations were achieved at both the single CpG site level (Pearson correlation: 0.69) and the 1kb window level (Pearson correlation: 0.84) (FIG. 13). To assess the methylation consistency at important regulatory elements, the average profile was calculated across all CpG island (CGI)

promoters, exon and CTCF insulators, and these results showed high correlation between ground truth and prediction (FIG. 14).

*Example 4: Inference of DNA methylation from high coverage whole genome sequencing*

5 To check if the prediction is biased by the DNA methylation prior, matched WGS and WGBS were generated from a cfDNA sample with 48% tumor content from a prostate cancer patient. The predicted methylation level from WGS at CGI promoters exhibited local hypermethylation around transcription start sites (TSS's) and global hypomethylation at surrounding regions in prostate cancer cfDNA compared with healthy donor cfDNA, which is  
10 also observed in the ground truth WGBS of cancer-healthy pairs (FIG. 4). To unbiasedly quantify how much DNA methylation dynamics could be captured by the prediction from WGS, we called Differential Methylation Regions (DMRs) in the cancer-healthy pair with predicted and ground truth methylation levels, respectively. It was found that there are 74% of DMRs detected in WGBS that could be predicted in WGS (FIG. 5). The heatmap of DNA  
15 methylation level in DMRs called using WGBS clearly shows that the prediction of methylation dynamics from WGS could capture most of DNA methylation changes between samples from the cancer patient and healthy individual (FIG. 6). The methylation level dynamics at individual intergenic and promoter regions that are often hyper-methylated in prostate cancer and found similar concordance were evaluated (FIG. 7, FIG. 15A – FIG.  
20 15E).

*Example 5: Tissue-of-origin prediction based on ground truth (WGBS) and predicted (WGS) DNA methylation level in cancer and healthy individuals*

Recent studies have suggested the potential to predict tissue-of-origin of cfDNA  
25 based on analysis of DNA methylation. The deconvolution of tissue-of-origin was explored using DNA methylation levels that were measured and predicted using WGBS and WGS, respectively. WGBS of cfDNA was generated from one prostate cancer patient and two healthy individuals and compiled a set of reference methylomes for deconvolution of tissue-of-origin. Similar tissue-of-origin profiles were found based on predicted and measured  
30 methylation levels for each of the three individuals (FIG. 16A – FIG. 16D), with clear distinctions between the cancer and healthy individuals. The tumor fraction estimated using the tissue-of-origin deconvolution (33-79%) was similar to the tumor fraction estimated

(48%) based on somatic alterations using established methods ABSOLUTE (Carter et al 2012).

*Example 6: Inference of DNA methylation and tissue-of-origin from ultra-low-pass whole genome sequencing*

5 Deep coverage WGS remains costly for routine clinical application. It was sought to determine whether DNA methylation levels could be predicted using ultra-low-pass whole-genome sequencing (0.1x coverage, ULP-WGS) and infer tissue-of-origin. Matched ULP-WGS and WGBS of cfDNA were generated from 104 individuals, including healthy donors  
10 and breast and prostate cancer patients. The methylation level was first examined at important regulatory elements, such as CGI promoters, and observed similar average methylation profile in predicted and measured methylation levels from ULP-WGS and WGBS, respectively (FIG. 17A and FIG. 17B). To calculate the pairwise concordance between paired predicted and measured signals, the methylation density was binned and calculated in 1kb  
15 non-overlapped windows. High concordance between predicted and measured methylation levels (FIG 8) was found. We next applied the deconvolution approach for tissue-of-origin and obtained similar results based on the matched ULP-WGS and WGBS (FIG 8).

*Example 7: Inference of tissue-of-origin profiles across many samples reflects expected subtypes of cancer and sites of metastasis in patients*

20 After validating that methylation levels using ULP-WGS could be predicted, ccInference was applied to a much larger cohort with 1628 ULP-WGS sample from prostate, breast and healthy conditions (Adalsteinsson et al 2017). The tissue-of-origin profiles were inferred in each sample and found high concordance of the tumor fraction estimated based on  
25 predicted DNA methylation and measured based on analysis of somatic copy number alterations using ichorCNA (Adalsteinsson et al 2017). It was further found that the tissue-of-origin signal to reflect the expected subtypes of cancer and sites of metastasis were confirmed in these patients .

30 *Example 8: Performance in Tissue-of-Origin Prediction (in silico mixture)*

The Encyclopedia of DNA Elements (ENCODE) Project seeks to identify functional elements in the human genome using designated cell types. ENCODE cell lines were analyzed as described below. Cell lines analyzed (FIG. 19A) included the following: **H1**

human embryonic stem cells (Cellular Dynamics); **HepG2**, which is a cell line derived from a male patient with liver carcinoma (ATCC Number HB-8065); **K562**, which is an immortalized cell line produced from a female patient with chronic myelogenous leukemia (CML); and **GM12878**, which is a lymphoblastoid cell line produced from the blood of a female donor with northern and western European ancestry by Epstein Barr Virus (EBV) transformation, which has a relatively normal karyotype (Coriell Institute for Medical Research; Catalog ID GM12878).

Reads in a simulated bam file were randomly sampled from WGBS in 2-9 ENCODE cell lines. Each sample has approximately 3 million reads (0.1X) with different mixed proportion from undetermined number of reference cell lines. A machine learning approach was used to infer the base pair resolution DNA methylation level from fragment size information in whole genome sequencing (WGS). The predicted DNA methylation, from not only high coverage, but also dozens of ultra-low-pass WGS (ULP-WGS), showed high concordance with the ground truth DNA methylation level from WGBS in the same cancer patients. Furthermore, by using hundreds of WGBS datasets from different tumor and normal tissues/cells as the reference map, cfDNA's tissue-of-origin status was deconvoluted by inferred DNA methylation level at ULP-WGS from the cell lines described above.

FIG. 19A shows true value (known from ground truth (top)), predicted value based on inference, and a 1% root mean square error measure of the difference between the two values.

The same approach was applied to thousands of breast/prostate cancer samples and healthy individuals. The cfDNA's tissue-of-origin status in cancer patients showed high concordance with confirmed metastasis tissues from physicians (FIG. 19B, 19C). Interestingly, some clinical information, such as cancer grades/stages, seemed to be correlated with cfDNA's tissue-of-origin status. Overall, these methods provide for cfDNA's application in clinical diagnosis and monitoring.

The methods and results disclosed herein demonstrate that analysis of single base DNA methylation is possible based on genomic sequencing of cfDNA. This overcomes a major hurdle associated with bisulfite conversion of limited amounts of cfDNA and may enable epigenomic analysis in a greater fraction of patient cfDNA samples. As shown herein, predicted and measured methylation levels at CGI's, promoters, exons, and CTCF insulators are concordant between WGS and WGBS, respectively, and that many of the same DMRs can be identified between cancer and healthy samples using WGS. The predictions are most



accurate for CpG-dense regions of the genome, and further work is required to improve the predictions in CpG-poor regions. Disclosed herein are methods and results that demonstrate that analysis of tissue-of-origin is feasible based on DNA methylation levels predicted from WGS or ULP-WGS of cfDNA. Recent studies have suggested that analysis of tissue-of-  
5 origin is possible based on analysis of nucleosome spacing in WGS of cfDNA, but the lack of reference nucleosome maps in different tumor may limit its application. Although it is not expected to replace bisulfite sequencing for direct measurement of methylation levels, disclosed herein are generalizable methods that could enable epigenomic analysis of cfDNA samples with limited material, or samples that would otherwise only undergo genomic  
10 profiling.

The results described herein above, were obtained using the following methods and materials.

### **Clinical Samples**

Cancer patient blood samples were obtained from appropriately consented patients as  
15 described in Adalsteinsson et al Nature Communications 2017. Healthy donor blood samples were obtained from appropriately consented individuals from Research Blood Components (<http://researchbloodcomponents.com/services.html>). Samples were collected and fractionated as described in Adalsteinsson et al Nature Communications 2017.

### **20 Whole genome bisulfite sequencing of cfDNA**

Library construction was performed on 25 ng of cfDNA using the Hyper Prep Kit (Kapa Biosystems) with NEXTFlex Bisulfite-Seq Barcodes (Bioo Scientific) and HiFi Uracil+ polymerase (Kapa Biosystems) for library amplification. NEXTFlex Bisulfite-Seq Barcodes were used at a final concentration of 7.5 uM and the EZ-96 DNA Methylation-  
25 Lightning MagPrep kit (Zymo Research) was used for bisulfite conversion of the adapter-ligated cfDNA prior to library amplification. Libraries were sequenced using the HiSeq2500 (Illumina) with a 20% spike of PhiX.

### **Whole genome sequencing of cfDNA**

30 Library construction was performed on 5 - 20 ng of cfDNA using the Hyper Prep Kit (Kapa Biosystems) and custom sequencing adapters (Integrated DNA Technologies). A Hamilton STAR-line liquid handling system was used to automate and perform the method. Libraries were sequenced using the HiSeq2500 (Illumina).

### Model development and training

Initiation matrix was summarized based on the states of the first CpG in each DNA fragment separately. Nonparametric model was used to calculate initiation and transition matrix by taking account of the distance with adjacent CpG sites. Gaussian mixture model was applied to model the emission likelihood of each of the three fragmentation features (fragment length, coverage and distance to the end of fragment). DNA methylation prior, estimated from methylation level at genomic DNA in healthy individual, is utilized to calculate the posterior emission probability of hidden status in the decoding step, which model the base DNA methylation differences in different genomic context (details in Supplemental Method). For example, the probability of observing methylated event  $em$  given that it located at CpG site with methylation prior  $k$  is:

$$Pr(e_m) = \frac{Pr(e_m|k)Pr(k)}{Pr(e_m|k)Pr(k) + Pr(e_u|1-k)(1-Pr(k))}$$

### Tissue Deconvolution Mapping

Quadratic programming was utilized to solve the constrained optimization problem. The method followed the tissue deconvolution algorithm described in Sun et al PNAS with some adaptations as disclosed below.

### ichorCNA analysis

Estimation of tumor fraction was performed using ichorCNA as described previously in Adalsteinsson et al Nature Communications 2017.

### Code Availability:

Code for ccInference and associated scripts are publically available in Bitbucket: <https://bitbucket.org/dnaase/ccinference>

### Data preprocess

Each fragments covered CpGs in autosomal chromosomes reference genome (hg19/GRch37) are used for the analysis. Fragment length more than 500bp are discarded. Regions with coverage more than 250X are also discarded. Only high quality reads are considered in the following analysis (high quality: unique mapped, no PCR duplicate, both of

end are mapped with mapping quality more than 30 and properly paired). To calculate the methylation status for each CpG in each fragment, only bases with base quality more than 5 are used. For WGBS data, the methylation status of CpGs is starting to be counted from the first converted cytosine in each of the fragment as described in Bis-SNP (Liu et al. 2012  
 5 Genome Bio). Fragment coverage are normalized by dividing the total number of high quality reads in the bam file. Z-score of fragment length, normalized coverage and distance to the end of fragment are used as features for HMM model. All details are implemented in ‘CpgMultiMetricsStats.java’. Methylation level from WGBS is called by Bis-SNP.

### 10 **Bayesian non-homogeneous Hidden Markov Model**

Two states Hidden Markov Model (HMM) is implemented as described in Rabiner 1989 at Jahmm framework with some adaptations to our problem. Baum-Welch algorithm is used to estimate the parameters with maximum of 50 iterations. All details are implemented in ‘CcBayesianNhmmV5.java’

15

#### **Initiation and transition probability**

The initiation probability of each state with the same offset from the start of the fragment is averaged by the states of first CpGs with the same offset range at all the high quality fragments. CpGs within the same 5bp bin are counted as in the same offset range. The  
 20 transition probability matrix between states is also calculated separately for each of the possible distance range (also 5bp bin) to the previous CpG.

#### **Emission distributions**

Three features (fragment length, normalized coverage and distance to the end of  
 25 fragment) are modeled by Multivariate Mixture Gaussian distribution. Two components mixture of Gaussian distribution is used to model each of the feature separately.

$$Pr(e_m|k) = (1 - \pi) * N(\mu_i, \sigma_i^2) + \pi * N(\mu_j, \sigma_j^2)$$

In the Viterbi decoding step, methylation prior for each single CpG estimated from genomic DNA in buffycoat sample from healthy individual (Jensten et al. 2015 Genome Biology) is  
 30 only used to calculate the emission probability for each CpG.

**K-means initialization for HMM model**

K-means++ algorithm () is used to estimate the initiation state of each CpG in each fragment by three fragmentation features vector with maximum 10,000 iterations. Due to the random initiation status of K-means algorithm, the same clustering process is calculated 20  
5 times and the best clustering result is selected based on euclidean distance between two clusters. After K-means initialization, the methylated and unmethylated states are identified by the mean methylation level of each state from the methylation prior used at 2.2. Then the initiation parameters of HMM model is estimated. All details are implemented in ‘KMeansPlusLearner.java’.

10

**KL divergence**

Kullback-Leibler distance is used to estimate the divergence of new HMM during Baum-Welch re-estimation. Since methylation prior is used for the decoding step and is different at different CpG site, 10,000 random fragments with minimum of 5 CpGs is selected  
15 to calculate the Kullback-Leibler distance. If the distance between new and old HMM is less than 0.005 or the changes of distance is less than 1%, the model is considered as converged.

**Performance evaluation**

Comparison on binary methylation status of each CpG in each fragment (WGBS)  
20 CcInference is trained and decoded at WGBS data without using any methylation information from the data itself. Even number of methylated and unmethylated CpGs is random sampled from WGBS bam file. Prediction results are compared with ground truth methylation binary states in WGBS. Threshold is varied to identify methylated status at Viterbi decoding step in order to calculate ROC curve.

25

**Comparison on continuous methylation level at each CpG site and windows (paired WGBS and WGS)**

CcInference is trained and decoded at WGS data. Methylation level is calculated by aggregating the binary methylation status across fragments at each CpGs. The continuous  
30 methylation level is compared with methylation level obtained from WGBS at the same individual. For the comparison at low coverage WGS and WGBS data, methylation density at each 1kb bin is calculated instead of each single CpG.

### Comparison of methylation profiles at important regulatory elements (paired WGBS and WGS)

CcInference is trained and decoded at WGS data. Predicted methylation level is calculated as described in 3.2. Average methylation level around CpG island promoters, 5' end of exon, CTCF motif is calculated by Bis-Tools as described in Lay & Liu et al. 2015 Genome Res. CpG island definition is merged from three different resources: Takai & Jones 2001, Gardiner-Garden M, Frommer M 1987, Irizarry et al. 2009.

### Cancer/Normal Differential Methylation Regions (DMRs) analysis

DSS (Wu 2015 NAR) is applied to call DMRs at predicted methylation level from WGS and ground truth methylation level from WGBS in paired cancer-healthy samples. *DMLtest* with smoothing is applied before calling DMRs. Function *callDMR* with default parameter is used to call significant DMRs in. Due to the differences of coverage in WGS and WGBS, DMR within 2kb region are considered as in the same location for the overlapping analysis. Heatmap of methylation level in 20bp bin around each DMR is plotted as described in Lay & Liu et al. 2015 Genome Res.

### Tissue Deconvolution Mapping

To infer tissue of origin from low-pass WGBS or inferred WGBS patient data, patient WGBS data was modeled as a linear combination of reference methylomes. The weights were constrained to sum up to 1 so that the weights can be interpreted as tissue contribution to cfDNA. Quadratic programming was utilized to solve the constrained optimization problem. This method and approach closely follows the tissue deconvolution algorithm described in Sun et al PNAS.

Due to the low coverage of our low-pass data, 500bp tiling bins were taken with minimum of 5 reads and 3 CpGs across the genome in patient and reference data to compute the mean methylation level (Possible change to 1kb, min 10 reads, min 10 CpGs). To filter for differentially methylated regions (DMRs), the number of overlapping bins were first narrowed down to intersect with CpG islands and shores (with shores defined as 2kb regions adjacent to each CpG island). From the 25 reference methylomes, 422,297 common 500bp bins were picked that overlapped with CpG island and shores. The second step is to narrow down the number by using only the top 5% most variable regions. A final number of 422,927 DMRs were curated for deconvolution.

The choice of reference methylome is as follows: the list of reference methylome were incorporated as used in Sun et al PNAS, but omitted colon, adrenal glands, esophagus, and adipose tissues from the Roadmap consortium because those samples were never published due to quality control. Colon and Esophagus samples were substituted back in from  
5 the IHEC and ENCODE consortium, respectively. Placenta reference was omitted as well because the sample was irrelevant to our analysis. Several cancer references were incorporated relevant to the analysis: 6 TCGA triple-negative breast cancer samples, one of which is an adjacent normal, one MBC sample, and four metastatic prostate cancer samples.

The deconvolution of patient samples fall largely into three categories: breast cancer,  
10 prostate cancer, and healthy controls. In the deconvolution process, references were picked that were relevant to the patient samples. For example, if deconvoluting a breast sample, prostate references were omitted in our reference methylome. To define tumor fraction, tissue contribution fractions from relevant cancer references were summed up.

#### 15 **Other Embodiments**

From the foregoing description, it will be apparent that variations and modifications may be made to the methods described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.

The recitation of a listing of elements in any definition of a variable herein includes  
20 definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

All patents and publications mentioned in this specification are herein incorporated by  
25 reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.

What is claimed is:

1. A method of characterizing DNA in a biological sample, the method comprising:
  - (a) isolating fragments of DNA from a biological sample;
  - (b) constructing a library comprising said fragments;
  - 5 (c) sequencing the library; and
  - (d) detecting alterations in the fragmentation pattern in methylated and unmethylated DNA of cell free DNA (cfDNA) and genomic DNA (gDNA), wherein the fragmentation pattern in each DNA fragment identifies the DNA methylation pattern.
- 10 2. A method of characterizing DNA in a biological sample, the method comprising:
  - (a) isolating fragments of DNA from a biological sample;
  - (b) constructing a library comprising said fragments;
  - (c) sequencing the library; and
  - 15 (d) detecting alterations in the fragment length, fragment coverage, and distance to fragment end in methylated and unmethylated DNA of cell free DNA and genomic DNA, wherein the fragmentation pattern in each DNA fragment identifies the DNA methylation pattern, thereby indicating that at least a fragment of the DNA in the sample was derived from a diseased cell or was
  - 20 derived from a healthy cell.
3. The method of claim 1 or 2, wherein prior to step (a), the gDNA is contacted with an enzyme that is capable of cutting the DNA at hypersensitive sites.
- 25 4. The method of claim 3, wherein the enzyme is Deoxyribonuclease I (DNase I).
5. The method of claim 3, wherein the enzyme is Transposase.
6. The method of claim 5, wherein the Transposase is TN5.
- 30 7. The method of any one of the preceding claims, wherein the sample comprises a limited amount of DNA.

8. The method of any one of the preceding claims, wherein the method identifies the binary methylation status at each CpG in each DNA fragment.
9. The method of any one of the preceding claims, wherein the sequencing is ultra-low pass,  
5 exome sequencing, or whole genome sequencing.
10. The method of any one of claims 1 to 8, wherein the sequencing is deep sequencing.
11. The method of any one of claims 1 to 8, wherein the sequencing is capture based  
10 sequencing.
12. The method of claim 11, wherein the capture based sequencing has off-target reads that span the genome.
13. The method of any one of claims 1 to 8, wherein the sequencing is at about 0.01-30X  
15 genome sequencing coverage.
14. The method of any one of the preceding claims, wherein the biological sample is a tissue sample or a liquid biological sample selected from the group consisting of blood, plasma,  
20 serum, cerebrospinal fluid, phlegm, saliva, urine, semen, prostate fluid, breast milk, and tears.
15. The method of any one of claims 1 to 13, wherein the biological sample is a fresh or archival sample derived from a subject having a cancer selected from the group consisting of prostate cancer, metastatic prostate cancer, breast cancer, triple negative breast cancer, lung  
25 cancer, multiple myeloma, pancreatic cancer, and colon cancer.
16. The method of any one of claims 2 to 13, wherein the diseased cell is derived from a patient having cancer, diabetes, kidney disease, Alzheimer's disease, myocardial infarction, stroke, autoimmune disorders, transplant rejection, Multiple sclerosis, type I diabetes, a  
30 cancer, and a disease that results in increased cell death.
17. The method of any one of the preceding claims, wherein the tissue of origin of the biological sample is selected from the group consisting of an esophageal cell, B-Cell, breast,



brain cortex, prostate cancer, small intestine, heart, large intestine, liver, lung, neutrophil, pancreas, or T-Cell.

18. A method of identifying a subject as having a disease, the method comprising:

- 5 (a) isolating fragments of DNA from a biological sample;  
(b) constructing a library comprising said fragments;  
(c) sequencing the library; and  
(d) detecting alterations in the fragmentation pattern in methylated and unmethylated  
DNA of cell free DNA and genomic DNA, wherein the detection of  
10 differences in the fragmentation pattern indicates that the subject has a disease,  
and failure to detect such alterations indicates that the subject does not have a  
disease; thereby identifying the subject as having or not having a disease.

19. A method of monitoring a subject's response to treatment of a disease, the method  
15 comprising:

- (a) isolating fragments of DNA from a biological sample obtained from the subject  
before and after treatment;  
(i) constructing a library comprising said fragments;  
(ii) sequencing the library;  
20 (iii) detecting alterations in the fragmentation pattern in methylated and  
unmethylated DNA of cell free DNA and genomic DNA before and  
after treatment; thereby monitoring the subject's response to treatment.

20. A method of diagnosing the presence or absence of a disease or cancer in a subject, the  
25 method comprising:

- (a) isolating fragments of DNA from a biological sample;  
(b) constructing a library comprising said fragments;  
(c) sequencing the library; and  
(d) detecting alterations in the fragmentation pattern in methylated and unmethylated  
30 DNA of cell free DNA and genomic DNA relative to a healthy reference  
sample; wherein the detection of differences in the fragmentation pattern  
between the subject and the reference sample indicates that the subject does

have a disease r, and failure to detect such alterations indicates that the subject does not have a disease.

21. The method of any one of claims 18 to 20, wherein prior to the step of isolating  
5 fragments of DNA from a biological sample, the gDNA is contacted with an enzyme that is capable of cutting the DNA at hypersensitive sites.
22. The method of claim 21, wherein the enzyme is Deoxyribonuclease I (DNase I).
- 10 23. The method of claim 21, wherein the enzyme is Transposase.
24. The method of claim 23, wherein the Transposase is TN5.
25. The method of any one of claims 18 to 24, wherein the sample comprises a limited  
15 amount of DNA.
26. The method of any one of claims 18 to 25, wherein the method identifies the binary methylation status at each CpG in each DNA fragment.
- 20 27. The method of any one of claims 18 to 26, wherein the sequencing is ultra-low pass, exome sequencing, or whole genome sequencing.
28. The method of any one of claims 18 to 25, wherein the sequencing is deep sequencing.
- 25 29. The method of any one of claims 18 to 25, wherein the sequencing is capture based sequencing.
30. The method of claim 29, wherein the capture based sequencing has off-target reads that span the genome.
- 30 31. The method of any one of claims 18 to 25, wherein the sequencing is at about 0.01-30X genome sequencing coverage.

32. The method of any one of claims 18 to 31, wherein the biological sample is a tissue sample or a liquid biological sample selected from the group consisting of blood, plasma, serum, cerebrospinal fluid, phlegm, saliva, urine, semen, prostate fluid, breast milk, and tears.
- 5 33. The method of any one of claims 18 to 31, wherein the biological sample is a fresh or archival sample derived from a subject having a cancer selected from the group consisting of prostate cancer, metastatic prostate cancer, breast cancer, triple negative breast cancer, lung cancer, multiple myeloma, pancreatic cancer, and colon cancer.
- 10 34. The method of any one of claims 18 to 31, wherein the diseased cell is derived from a patient having cancer, diabetes, kidney disease, Alzheimer's disease, myocardial infarction, stroke, autoimmune disorders, transplant rejection, Multiple sclerosis, type I diabetes, a cancer or disease having a pre-determined tissue of origin, and a disease that results in increased cell death.
- 15 35. The method of any one of claims 18 to 34, wherein the tissue of origin of the biological sample is selected from the group consisting of an esophageal cell, B-Cell, breast, brain cortex, prostate cancer, small intestine, heart, large intestine, liver, lung, neutrophil, pancreas, or T-Cell.
- 20 36. A computer-implemented method, comprising:
- (a) receiving, by at least one computer processor executing specific programmable instructions configured for the method, sequence data;
  - (b) filtering, by the at least one computer processor, the sequence data from the training set, based on the following parameters: (i) the fragment length of each individual DNA fragment within the plurality; (ii) the fragment coverage;
  - 25 (iii) the distance to fragment end; and (iv) a reference methylation pattern;
  - (c) generating, by the at least one computer processor, a Bayesian non-homogenous Hidden Markov Model, using the parameters (i) to (iv) in step (b) above, to
  - 30 predict DNA methylation patterns from DNA sequence reads;
  - (d) receiving, by at least one computer processor executing specific programmable instructions configured for the method, sequence data,

wherein the sequence data is obtained from cell free DNA or genomic DNA isolated from a biological sample obtained from a subject, wherein the gDNA has been contacted with an enzyme;

(e) generating, by the at least one computer processor, from the sample sequence data, data corresponding to (i) the fragment length of each individual DNA fragment within the plurality; (ii) the fragment coverage; and (iii) the distance to fragment end; and

(f) determining, by the at least one computer processor, using the Bayesian non-homogenous Hidden Markov Model, using the parameters (i) to (iii) in step (e) above, the predicted DNA methylation pattern of the ctDNA or gDNA in the biological sample.

37. The computer-implemented method of claim 36, wherein the predicted DNA methylation pattern of the ctDNA is deconvoluted, by the at least one computer processor, using a non-overlapping window analysis and quadratic programming, to obtain the tissue of origin of the biological sample.

38. The computer-implemented method of claim 36, wherein the enzyme is capable of cutting the DNA at hypersensitive sites.

39. The computer-implemented method of claim 38, wherein the enzyme is Deoxyribonuclease I (DNase I).

40. The computer-implemented method of claim 38, wherein the enzyme is Transposase.

41. The computer-implemented method of claim 40, wherein the Transposase is TN5.

42. The computer-implemented method of any one of claims 36 to 41, wherein the sample comprises a limited amount of DNA.

43. The computer-implemented method of any one of claims 36 to 42, wherein the method identifies the binary methylation status at each CpG in each DNA fragment.

44. The computer-implemented method of any one of claims 36 to 43, wherein the sequencing is ultra-low pass, exome sequencing, or whole genome sequencing.

5 45. The computer-implemented method of any one of claims 36 to 43, wherein the sequencing is deep sequencing.

46. The computer-implemented method of any one of claims 36 to 43, wherein the sequencing is capture based sequencing.

10 47. The computer-implemented method of claim 46, wherein the capture based sequencing has off-target reads that span the genome.

48. The computer-implemented method of any one of claims 36 to 43, wherein the sequencing is at about 0.01-30X genome sequencing coverage.

15

49. The computer-implemented method of any one of claims 36 to 48, wherein the biological sample is a tissue sample or a liquid biological sample selected from the group consisting of: blood, plasma, serum, cerebrospinal fluid, phlegm, saliva, urine, semen, prostate fluid, breast milk, and tears.

20


50. The computer-implemented method of any one of claims 36 to 48, wherein the biological sample is a fresh or archival sample derived from a subject having a cancer selected from the group consisting of prostate cancer, metastatic prostate cancer, breast cancer, triple negative breast cancer, lung cancer, multiple myeloma, pancreatic cancer, and colon cancer.

25

51. The computer-implemented method of any one of claims 36 to 48, wherein the reference methylation pattern is derived from a patient having cancer, diabetes, kidney disease, Alzheimer's disease, myocardial infarction, stroke, autoimmune disorders, transplant rejection, Multiple sclerosis, type I diabetes, a cancer or disease having a pre-determined  
30 tissue of origin, and a disease that results in increased cell death.

52. The computer-implemented method of any one of claims 36 to 51, wherein the tissue of origin of the biological sample is selected from the group consisting of an esophageal cell, B-

Cell, breast, brain cortex, prostate cancer, small intestine, heart, large intestine, liver, lung, neutrophil, pancreas, or T-Cell.







FIG. 1B-1

1. DNA methylation (gDNA) is tissue specific





## FIG. 1B-2

## 2. Bisulfite -&gt;DNA degradation

DNA bisulfite conversion





FIG. 1B-3





FIG. 1B-4







FIG. 3







FIG. 4

FIG. 5







FIG. 6



FIG. 7






FIG. 8




FIG. 9

FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11




FIG. 12






FIG. 13




FIG. 14




FIG. 15




FIG. 15 (Continued)




FIG. 15 (Continued)




FIG. 15 (Continued)




FIG. 15 (Continued)




FIG. 16






FIG. 16 (Continued)




FIG. 16 (Continued)




FIG. 16 (Continued)




FIG. 17




FIG. 18






FIG. 19

A. Ground truth (2-4 samples mixture)



B. RMSE (2-9 samples mixture)



1%



FIG. 19 (Continued)

B.






FIG. 19 (Continued)

C.





## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/45583

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(8) - C12Q 1/68; G06F 19/18, 19/24 (2017.01) CPC - C12Q 1/6883, 6886, 1/6809, 1/6869; G06F 19/18, 19/24		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) See Search History Document		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See Search History Document		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See Search History Document		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2016/015058 A2 (University of Washington) 28 January 2016 (28.01.2016). Especially [0009], [0012], [0043], [0074], [0079], [00107], [00126], [00139]	1-6, 18-24, 38-41, 42/(38-41)
Y	US 2015/0011403 A1 (The Chinese University of Hong Kong) 8 January 2015 (08.01.2015). Especially para [0085], [0088], [0098], [0100], [0123], [0164], [0232], [0254], [0258], [0525], [0560]	1-6, 18-24, 36-42
Y	US 2014/0142942 A1 (Accumente LLC) 22 May 2014 (22.05.2014). Especially para [0032], [0064]	36-42
A	Tsompana et al. Chromatin accessibility: a window into the genome. Epigenetics Chromatin 20 November 2014 Vol 7 No 1 Pages 1-16. Especially pg 4 fig 1 and entire article [review of the field]	1-6, 18-24, 36-42
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 9 October 2017		Date of mailing of the international search report <b>06 NOV 2017</b>
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300		Authorized officer: Lee W. Young  PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/45583

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: 7-17, 25-35, 43-52  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.